Edition:
United States

EyeGate Pharmaceuticals Inc (EYEG.OQ)

EYEG.OQ on NASDAQ Stock Exchange Capital Market

1.27USD
15 Dec 2017
Change (% chg)

$0.07 (+5.83%)
Prev Close
$1.20
Open
$1.20
Day's High
$1.29
Day's Low
$1.20
Volume
49,578
Avg. Vol
28,758
52-wk High
$3.89
52-wk Low
$0.90

Select another date:

Tue, Nov 14 2017

BRIEF-Eyegate Pharmaceuticals posts Q3 ‍net loss $4.1 mln vs $3.4 mln a year ago

* Eyegate Pharmaceuticals reports third quarter 2017 financial results and provides business update

BRIEF-EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery

* EyeGate completes enrollment in phase 2b clinical trial of EGP-437 for cataract surgery

BRIEF-Eyegate Pharmaceuticals Q2 revenue $148,000

* Eyegate Pharmaceuticals reports second quarter 2017 financial results and provides business update

BRIEF-Eyegate Pharma enrolls first patient in phase 2b clinical study

* Eyegate Pharma enrolls first patient in phase 2b clinical study of EGP-437 for cataract surgery Source text for Eikon: Further company coverage:

BRIEF-Armistice Capital LLC reports 9.9 percent passive stake in Eyegate Pharmaceuticals Inc

* Armistice Capital LLC reports 9.9 percent passive stake in Eyegate Pharmaceuticals Inc, as of June 9, 2017 Source text: (http://bit.ly/2sM4eCk) Further company coverage:

Select another date: